Teleflex price target raised to $247 from $240 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Teleflex to $247 from $240 and keeps a Hold rating on the shares after its Q2 results and guidance raise. The company’s constant-currency revenue growth outlook moves higher and contemplates IABP pump share gains in Q4, with the tailwind attributable to strong organic performance in the first half and what the management thinks is a share gain opportunity following an FDA letter suggesting that physicians evaluate alternatives to competitor Getinge’s product, the analyst tells investors in a research note.